Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

Sirtex shares drop on $26m loss

Marnie Banger  |  23 Aug 2017Text size  Decrease  Increase  |  

Page 1 of 1

SYDNEY - [AAP] Shares in liver cancer treatment developer Sirtex Medical (ASX SRX) have plunged after it ended a challenging year with a $26.3 million loss.

Sirtex said a previously announced $90.5 million writedown in the value of its clinical and research and development assets led to the loss, along with restructuring costs.

Excluding those one-off items, slowing sales growth contributed to a 21 per cent drop in underlying profit to $42.4 million in the 12 months to June 30--the first fall since 2010/11.

Sirtex said it had a 5.4 per cent lift in global sales of doses of its core technology, a radiation therapy for liver cancer.

However, sales growth in its largest market of America slowed to 4.6 per cent.

The company says referrals for the technology declined as competition for patients increased, including from drug-based therapies.

Sirtex also spent $4.1 million on restructuring the business in 2016/17, mostly on redundancies.

The company said it is committed to improving its market share and has cut costs to improve its financial performance, but some challenges may continue.

"We do anticipate the market conditions that manifested in FY17 may persist through FY18," Sirtex said in a statement.

"Though the resetting of the business means we are now better positioned and more focussed on growing our core SIR-Spheres microspheres business."

Sirtex shares were down $1.85, or 11.4 per cent, at $14.41 at 1500 AEST.

IMPAIRMENTS HIT SIRTEX AS SALES GROWTH SLOWS:

* Full-year loss of $26.3 million vs $53.6m profit

* Revenue up 0.9pct at $236.9m

* Final unfranked dividend 30 cents, unchanged

 

AAP logo image

© [2017] Australian Associated Press Pty Limited (AAP) or its Licensors. This is the Morningstar service with content provided by AAP where indicated. AAP reserves all rights, including copyright, in services provided by it. The information in the service is for personal use only, does not constitute financial product advice (whether general or personal) and may not be re-written, copied, re-sold or re-distributed, framed, linked or otherwise used whether for compensation of any kind or not, without the prior written permission of AAP. You should seek advice from a professional financial adviser before making decision to acquire or dispose of a financial product.

This service is published for general information purposes only without assuming a duty of care. AAP is not in the business of providing financial product advice (whether personal or general advice), and gives no warranty, guarantee or other representation about the accuracy of the information or images contained in this service. AAP is not liable for errors, omissions in, delays or interruptions to or cessation of the services through negligence or otherwise. The globe symbol and "AAP" are registered trademarks.